查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1737207

全球铜绿病菌感染药物市场规模（按类型、应用、地区、范围和预测）

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size By Type, By Application, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

抗药性病菌感染药物的市场规模及预测

2024 年，抗抗药性病菌感染药物的市场规模价值 42.406 亿美元，预计到 2032 年将达到 67.2325 亿美元，2026 年至 2032 年的复合年增长率为 5.93%。

推动全球抗药性病菌感染药物市场的因素

抗药性病菌感染药物市场的市场驱动因素可能受到多种因素的影响。

  • 抗药性感染疾病增加：已知铜绿假单胞菌对多种抗生素具有抗药性。随着抗药性细菌的不断增长，对抗这些疾病的有效药物需求日益增长。
  • 提高认知度和诊断水平：随着诊断方法的进步和医护人员认知度的提高，病菌感染现在可以更准确地识别。认知度的提高也导致了对有针对性的治疗的需求增加。
  • 医疗保健支出增加：由于全球医疗保健支出的增加，新药的研究和开发，特别是针对铜绿假单胞菌等抗药性细菌的药物，正在获得更多的资金。
  • 管道创新：药物发现的进步推动了针对抗药性病菌感染的更有效治疗方法的开发，包括新的作用机制、联合治疗和新的药物输送方法。
  • 监管措施：监管机构可能会提供市场独占权或快速通道程序，作为鼓励开发抗生素抗药性药物的手段，这可能会鼓励对该领域的投资。
  • 铜绿假单胞菌是医院内获得性感染的常见病原体，尤其容易发生在免疫力的病人和留置医疗设备的病人。此类疾病的发生率不断上升，对有效治疗方法的需求也日益增长。
  • 全球化与旅行：由于国际旅行的便利，铜绿假单胞菌和其他抗生素抗药性细菌大量繁殖，因此不仅在某些地区，而且在世界各地都需要有效的治疗方法。
  • 公共卫生问题：抗生素抗药性已被全球公认为严重的公共卫生危害。针对抗药性病菌感染的药物市场可能会受到政府应对此议题的倡议、公众意识提升宣传活动以及医疗专业人员、研究人员和政策制定者之间的合作努力的影响。

限制全球病菌感染药物市场的因素

有多种因素可能会对抗药性病菌感染药物市场产生阻碍因素或构成挑战。

  • 治疗成本高：开发精确针对抗药性菌株的药物需要大量的研发，并会增加製造成本，从而导致治疗方案成本增加，并限制某些患者和医疗保健系统获得治疗的机会。
  • 治疗方案有限病菌感染可能对多种抗生素产生抗药性，这使得新开发治疗铜绿假单胞菌感染变得困难。治疗方案的匮乏可能会阻碍市场扩张，尤其是在抗药性导致核准的药物失效的情况下。
  • 监管障碍：严格的药品核准监管标准，使得治疗抗药性病菌感染的新药难以进入市场。满足安全性和有效性法规要求既困难又昂贵。
  • 与现有疗法的竞争：如果现有抗生素和治疗方案继续占据市场主导地位，针对抗药性菌株的新药可能难以进入市场。医疗保健专业人员和医生可能更倾向于那些经过验证的治疗方法，而不是那些较新、知名度较低的治疗方法。
  • 疾病管理的复杂性：免疫力的患者和患有囊肿纤维化等潜在疾病的患者更容易病菌感染。除了药物治疗外，还需要支持治疗和感染控制措施来控制这些感染疾病。
  • 多重抗药性的出现 已知铜绿假单胞菌透过多种机制（包括生物膜形成和助焊剂泵）对多种抗生素产生抗药性。抗药性机制的持续发展对製药公司和医疗保健相关人员来说都是一个严峻的问题。
  • 全球健康问题：针对抗药性病菌感染的药物市场可能受到社会经济因素、医疗保健可近性以及医疗基础设施的地理差异的影响。某些地区治疗和医疗资源的差异可能会阻碍市场扩张。

目录

第一章：抗药性病菌感染药物的全球市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章抗药性病菌感染药物的全球市场概况

  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球抗药性病菌感染药物市场（按类型）

  • 概述
  • 半合成青霉素
  • 头孢菌素类
  • 内酰胺类药物
  • 其他的

6. 全球抗药性病菌感染药物市场（依应用）

  • 概述
  • 医院
  • 诊所
  • 居家医疗

7. 全球抗药性病菌感染药物市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

8. 全球铜绿病菌感染药物市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • Achaogen Inc
  • Novartis AG
  • Biolytics Pharma
  • LegoChem Biosciences Inc
  • Inhibrx LP
  • ContraFect Corp
  • AmpliPhi Biosciences Corp
  • Melinta Therapeutics Inc
  • Shionogi & Co Ltd.

第十章 附录

  • 相关调查
简介目录
Product Code: 58818

Resistant Pseudomonas Aeruginosa Infections Drugs Market size And Forecast

Resistant Pseudomonas Aeruginosa Infections Drugs Market size was valued at USD 4240.6 Million in 2024 and is projected to reach USD 6723.25 Million by 2032, growing at a CAGR of 5.93% from 2026 to 2032.

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Drivers

The market drivers for the Resistant Pseudomonas Aeruginosa Infections Drugs Market can be influenced by various factors. These may include:

  • Rising Rate of Resistance-Infections: Pseudomonas aeruginosa is well-known for its capacity to become resistant to several different antibiotics. As resistance continues to build, the requirement for effective medications to address these illnesses grows.
  • Increasing Awareness and Diagnosis: Pseudomonas aeruginosa infections can be identified more accurately thanks to advancements in diagnostic methods and raised awareness among medical practitioners. The need for focused therapy is driven by this increased awareness.
  • Increasing Healthcare Expenditure: Research and development of novel medications, particularly those aimed against resistant bacterial illnesses such as Pseudomonas aeruginosa, is receiving more funding as global healthcare spending rises.
  • Pipeline Innovation: The development of more potent treatments for resistant Pseudomonas aeruginosa infections is facilitated by developments in drug discovery and development, including the investigation of novel mechanisms of action, combination therapies, and novel drug delivery methods.
  • Regulatory Initiatives: Regulatory bodies may offer market exclusivity periods or accelerated review procedures as means of encouraging the development of medications that combat antibiotic resistance. Investment in this field may be encouraged by these measures.
  • Pseudomonas aeruginosa is frequently implicated: in hospital-acquired infections, especially in patients with impaired immune systems and those utilising indwelling medical equipment. The demand for efficient treatment options is increased due to the rising incidence of these illnesses.
  • Globalisation and Travel: Pseudomonas aeruginosa and other antibiotic-resistant bacteria are more likely to proliferate due to the accessibility of international travel. Consequently, there is a worldwide need for efficient treatments rather than just one or two particular areas.
  • Public Health Concerns: Antimicrobial resistance is acknowledged globally as posing a serious hazard to public health. The market for medications that target resistant Pseudomonas aeruginosa infections may be impacted by government initiatives, public awareness campaigns, and cooperative efforts amongst healthcare professionals, researchers, and policymakers in an attempt to solve this issue.

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Restraints

Several factors can act as restraints or challenges for the Resistant Pseudomonas Aeruginosa Infections Drugs Market. These may include:

  • High Treatment Cost: Creating medications that precisely target resistant strains frequently necessitates a large amount of research and development, which can raise production costs. This results in more costly treatment choices, which restricts access for some patients and healthcare systems.
  • Restricted Therapeutic Options: Pseudomonas aeruginosa infections can become resistant to a number of antibiotics, making it difficult to find new medications to treat them. Market expansion may be hampered by a lack of therapeutic options, particularly if resistance renders already-approved medications ineffective.
  • Regulatory Obstacles: Strict regulatory standards for medication approval may make it difficult for novel medications intended to treat resistant Pseudomonas aeruginosa infections to enter the market. It takes a lot of effort and money to meet safety and effectiveness regulations.
  • Competition from Established Therapies: Newer medications that target resistant strains may find it challenging to acquire traction if established antibiotics and treatment plans continue to rule the market. Healthcare professionals and doctors might favour proven therapies over more recent, unfamiliar ones.
  • Complexity of Disease Management: Patients who have weakened immune systems or underlying medical disorders, such as cystic fibrosis, are more susceptible to Pseudomonas aeruginosa infections. In addition to medication therapy, managing these infections calls for supportive care and infection control measures.
  • Emergence of Multi-Drug Resistance: Pseudomonas aeruginosa is well known for its capacity to grow resistant to a number of antibiotics by a number of different mechanisms, such as the creation of biofilms and efflux pumps. The ongoing development of resistance mechanisms presents a serious problem for both pharmaceutical companies and medical professionals.
  • Global Health Issues: The market for medications that target resistant Pseudomonas aeruginosa infections can be impacted by socioeconomic variables, access to healthcare, and geographical variations in healthcare infrastructure. In some areas, disparities in treatment and healthcare resources may impede market expansion.

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segmentation Analysis

The Global Resistant Pseudomonas Aeruginosa Infections Drugs Market is Segmented on the basis of Type, Application, And Geography.

Resistant Pseudomonas Aeruginosa Infections Drugs Market, By Type

  • Semi-Synthetic Penicillin
  • Cephalosporin
  • Lactam Drugs
  • Others

Based on Type, the market is bifurcated into, Semi-Synthetic Penicillin, Cephalosporin, Lactam Drugs, and Others. The semi-synthetic penicillin drug is leading the segment with the largest market share is expected to grow at a decent pace during the forecast period. Due to pseudomonas aeruginosa multidrug resistance, this is the most commonly utilized therapy in the method of delivering medications that have been carefully chosen to target certain molecules. This demonstrates that combination therapy has a larger market share in the treatment of pseudomonas aeruginosa infections.

Resistant Pseudomonas Aeruginosa Infections Drugs Market, By Application

  • Hospital
  • Clinic
  • Home Care

Based on Application, the market is bifurcated into, Hospital, Clinic, and Home Care. Clinics are expected to have the largest share of the pseudomonas aeruginosa infection treatment market. Aminoglycosides are highly strong broad-spectrum antibiotics used to treat life-threatening infections in the clinic. They are an antibiotic class used to treat infections caused by aerobic gram-negative bacteria.

Resistant Pseudomonas Aeruginosa Infections Drugs Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Global Resistant Pseudomonas Aeruginosa Infections Drugs Market is classified into North America, Europe. North America is in the lead, led by the United States. The expansion of the pseudomonas aeruginosa infection treatment market in the United States is being fueled by a highly efficient healthcare system and advantageous reimbursement policies from both public and commercial health insurance providers.

Key Players

  • The major players in the Resistant Pseudomonas Aeruginosa Infections Drugs Market are:
  • Achaogen Inc
  • Novartis AG
  • Biolytics Pharma
  • LegoChem Biosciences Inc
  • Inhibrx LP
  • ContraFect Corp
  • AmpliPhi Biosciences Corp
  • Melinta Therapeutics Inc
  • Shionogi & Co Ltd.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET OVERVIEW

  • 4.1 Market Dynamics
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
  • 4.2 Porters Five Force Model
  • 4.3 Value Chain Analysis

5 GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Semi-Synthetic Penicillin
  • 5.3 Cephalosporin
  • 5.4 Lactam Drugs
  • 5.5 Other

6 GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Clinic
  • 6.4 Home Care

7 GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Achaogen Inc
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Novartis AG
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Biolytics Pharma
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 LegoChem Biosciences Inc
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Inhibrx LP
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 ContraFect Corp
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 AmpliPhi Biosciences Corp
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Melinta Therapeutics Inc
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Shionogi & Co Ltd.
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments

10 Appendix

  • 10.1 Related Research